Key Findings:  While the authors of the study highlight the fact that the precise mechanisms of ECS-based effects (especially those of CB1 and CB2 receptor sites) in the context of treating PD remains to be fully understood, they also expressed their hopes that CB1- and CB2-based agonism or antagonism of may provide hope in suspending the course of PD.
Type of Study:  Meta-analysis
Study Result:  Negative
Research Location(s):  China
Year of Pub:  2019
Cannabinoids Studied:  Cannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2
Citation:  Han QW, et al. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020; 96:109745. doi: 10.1016/j.pnpbp.2019.109745
Authors:  Han QW, Yuan YH, Chen NH